References in periodicals archive ?
The MicroPhage BAT(TM) test platform does not require any instrumentation and is simple to operate, enabling microbiology testing outside of traditional laboratory settings.
I am very excited with the opportunity to serve on the MicroPhage Board of Directors.
Building on original research licensed from the Colorado School of Mines, MicroPhage has adapted Bacteriophage Amplification, a natural biologic process, for identifying bacterial infections.
D, Director, Research and Development at MicroPhage, test performance at the three sites exceeded all study goals and performed at or near FDA requirements in more than 700 clinical samples.
The MicroPhage MRSA/MSSA Blood Culture Test requires no instrumentation and is comprised of two small reaction tubes for incubating blood culture specimens.
MicroPhage CEO Steve Lundy knows Taussig's expertise in diagnosis and management of respiratory diseases and his healthcare management experience will be valuable to the board in guiding the company's future.
Gary Mesch, chairman of MicroPhage commented "MicroPhage investors are confident the company will deliver badly needed diagnostic tools in the fight against MRSA and other HAIs.
This is a very exciting time for MicroPhage," said Ms.
In the first presentation, MicroPhage scientists reported that their novel platform to simultaneously identify Staphylococcus aureus bloodstream infections and determine antibiotic resistance or susceptibility can provide highly accurate results in just 5 hours.
Our initial commercial product, in addition to the suite of additional tests we will offer based on our Bacteriophage Amplification platform, represents a new era for the effective and cost-effective testing of hospital patients," said MicroPhage CEO, Steve Lundy.
Our initial commercial product, as well as the battery of additional tests we will offer based on our Bacteriophage Amplification platform, personifies a whole new paradigm for the effective and cost-effective testing of hospital patients," said MicroPhage CEO, Steve Lundy.
Revotar Biopharmaceuticals AG owns proprietary rights to the development of small molecule antagonist Microphage Migration Inhibitor (MIF), and the Junctional Adhesion Molecule-1 (JAM-1) and its interaction with LFA-1.
Encyclopedia browser ?
- Micronetics Standard MUMPS
- micronic filters
- micronized clay
- micronized mica
- Micronutrient Fertilizers
- micro-opto-electro-mechanical system
- Micro-opto-electro-mechanical systems
- micro-opto-mechanical system
- Micro-opto-mechanical systems
- Microorganism Genetics
- microphone preamp
- microphone throat tattoo
- microphone transducer
Full browser ?
- Microparticle Capture Enzyme Immunoassay
- Microparticle Enzyme Immunoassay
- microphone boom
- Microphone Checker